Latest News and Press Releases
Want to stay updated on the latest news?
-
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors New investment to fuel continued growth of 3M³ platform for the development of products in tissue...
-
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors New investment to fuel continued growth of 3M³ platform for the development of products in tissue...
-
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration...
-
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 - Authorization to start clinical trial in the US granted for rare paediatric bone disease ...
-
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 - Authorization to start clinical trial in the US granted for rare paediatric bone disease ...
-
Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation Dual designations granted for NVD-003 for the Treatment of Congenital Pseudarthrosis of the Tibia...
-
Novadip Biosciences to Present at the LifeSci Partners Summer Symposium Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage...
-
Novadip Biosciences to Present at the LifeSci Partners Summer Symposium Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage...
-
Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020 -Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and...
-
Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020 -Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and...